CPL - Chalmers Publication Library
| Utbildning | Forskning | Styrkeområden | Om Chalmers | In English In English Ej inloggad.

Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.

Jörgen Elgqvist ; Håkan Andersson ; Peter Bernhardt ; Tom Bäck ; Ingela Claesson ; Ragnar Hultborn ; Holger Jensen ; Bengt R Johansson ; Sture Lindegren ; Marita Olsson (Institutionen för matematiska vetenskaper, matematisk statistik) ; Stig Palm ; Elisabet Warnhammar Finnborg ; Lars Jacobsson
International journal of radiation oncology, biology, physics (1879-355X). Vol. 66 (2006), 4, p. 1228-37.
[Artikel, refereegranskad vetenskaplig]

PURPOSE: To elucidate the therapeutic efficacy of alpha-radioimmunotherapy of ovarian cancer in mice. This study: (i) estimated the minimum required activity (MRA), giving a reasonable high therapeutic efficacy; and (ii) calculated the specific energy to tumor cell nuclei and the metastatic cure probability (MCP) using various assumptions regarding monoclonal-antibody (mAb) distribution in measured tumors. The study was performed using the alpha-particle emitter Astatine-211 (211At) labeled to the mAb MX35 F(ab')2. METHODS AND MATERIALS: Animals were inoculated intraperitoneally with approximately 1 x 10(7) cells of the cell line NIH:OVCAR-3. Four weeks later animals were treated with 25, 50, 100, or 200 kBq 211At-MX35 F(ab')2 (n = 74). Another group of animals was treated with a nonspecific mAb: 100 kBq 211At-Rituximab F(ab')2 (n = 18). Eight weeks after treatment the animals were sacrificed and presence of macro- and microscopic tumors and ascites was determined. An MCP model was developed and compared with the experimentally determined tumor-free fraction (TFF). RESULTS: When treatment was given 4 weeks after cell inoculation, the TFFs were 25%, 22%, 50%, and 61% after treatment with 25, 50, 100, or 200 kBq (211)At-MX35 F(ab')2, respectively, the specific energy to irradiated cell nuclei varying between approximately 2 and approximately 400 Gy. CONCLUSION: As a significant increase in the therapeutic efficacy was observed between the activity levels of 50 and 100 kBq (TFF increase from 22% to 50%), the conclusion was that the MRA is approximately 100 kBq (211)At-MX35 F(ab')2. MCP was most consistent with the TFF when assuming a diffusion depth of 30 mum of the mAbs in the tumors.

Nyckelord: Animals, Antibodies, Monoclonal, therapeutic use, Astatine, therapeutic use, Data Interpretation, Statistical, Dose Fractionation, Female, Mice, Mice, Inbred BALB C, Mice, Nude, Ovarian Neoplasms, pathology, radiotherapy, secondary, Radiation Dosage, Radioimmunotherapy, methods, Radiopharmaceuticals, therapeutic use, Treatment Outcome

Denna post skapades 2010-04-30. Senast ändrad 2011-08-18.
CPL Pubid: 120978


Läs direkt!

Länk till annan sajt (kan kräva inloggning)

Institutioner (Chalmers)

Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi (GU)
Institutionen för biomedicin, avdelningen för medicinsk kemi och cellbiologi (GU)
Institutionen för matematiska vetenskaper, matematisk statistik (2005-2016)
Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för onkologi (GU)


Cell- och molekylärbiologi

Chalmers infrastruktur